Clinical trial · Interventional
A Study of Epoetin Beta (NeoRecormon) in Participants With Solid Tumors or Hematologic Malignancies
Optimizing Treatment of the Anaemia in Onco-Hematological Diseases With NeoRecormon 30,000 IU Once Weekly
NCT02564094CI-TRIAL-00024593completedPhase 4ClinicalTrials.gov clinicaltrialsProvenance
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
This study will evaluate the efficacy, safety, and pharmacoeconomics of treatment with subcutaneous (SC) epoetin beta (NeoRecormon) in participants with hematologic malignancies or solid tumors. The anticipated time on study treatment is 20 weeks, and the target sample size is 60 individuals.
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Anemia | — | UNRESOLVED | — |
Interventions
Interventions (1)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| Epoetin beta | Drug | — | UNRESOLVED |
Design
Arms and outcomes
Arms (1)
- type
- EXPERIMENTAL
- label
- Epoetin beta
- description
- Participants with hematologic or solid malignancies will receive epoetin beta for a treatment period of approximately 20 weeks.
- interventionNames
- Drug: Epoetin beta
Primary outcomes (3)
- measure
- Response rate according to hemoglobin level
- timeFrame
- At Week 4
- measure
- Transfusion requirement rate
- timeFrame
- From Weeks 5 to 12
- measure
- Predictive value of reticulocyte increase
- timeFrame
- At Week 2
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 18 Years
Show eligibility criteria text
Inclusion Criteria: * Adults at least 18 years of age * Multiple myeloma (MM), low-grade non-Hodgkin's lymphoma (NHL), chronic lymphocytic leukemia (CLL), breast cancer, lung cancer, or ovarian cancer * Anemia with low erythropoeitin (EPO) levels Exclusion Criteria: * Poorly controlled hypertension * Relevant acute or chronic bleeding requiring therapy within 3 months before study drug * Treatment with EPO within the last 6 weeks * Pregnant or breastfeeding females
References
Publications (0)
Data not yet available
No reference posted for this study.